JunCell Biotech to Present Updated Clinical Data of Non-Viral Vector-Engineered TIL Therapy GC203 at ASCO 2024

Recently,Juncell Therapeutics announced that it will present its findings at the American Society of Clinical Oncology Annual Meeting (2024 ASCO), to be held in Chicago, USA, from May 31 to June 4, 2024.World's First Non-Viral Vector Gene-Modified TILThe latest clinical research data of GC203.

The ASCO Annual Meeting is, to date, the largest international conference globally with the highest academic standards and authority, significantly advancing the field of clinical oncology. Each year, the meeting gathers top oncology experts, doctors, researchers, and pharmaceutical industry representatives from around the world. The conference also serves as the platform for the first disclosure of cutting-edge clinical oncology research findings and major discoveries on an international scale, alongside discussions on the latest treatment methods and technologies.

Abstract Number: 5552

Abstract Title: A Phase I Single-Arm, Open-Label Trial of Engineering Tumor-Infiltrating Lymphocytes with Membrane-Bound IL-7 for Recurrent Ovarian Cancer.

Sub-venue Name: Gynecological Oncology

Poster Presentation Time: June 3, 2024, 9:00 AM - 12:00 PM Central Time (US)

Presenter: Dr. Jing Guo from Shanghai Tenth People's Hospital

About GC203

GC203 relies on Juncell Therapeutics' independently developed, world-leading DeepTIL.^®Cell Enrichment and Expansion with NovaGMP^®Developed through a gene modification technology platform, based on natural TIL cells, and using non-viral vector-mediated genetic engineering techniques to enable TIL cells to stably express membrane-bound, self-aggregating cytokine IL-7.

No need for lymphatic drainage, no need for IL-2 combination, treatment received in a general ward,Several patients with highly malignant gynecological tumors, who had failed multiple lines of treatment, experienced significant tumor reduction and long-term relief after receiving GC203 infusion therapy. Among them, two patients achieved complete tumor clearance, reaching CR efficacy.Currently, the IND application for GC203 has been accepted by the CDE and is expected to be approved shortly to enter the registration clinical trial.

Hot Topic

Advances in Clinical Development of NK Cell Therapy

Opportunities and Challenges in the Original Development of Cell Therapy Drugs

Development Strategies for iPSC-Derived NK Cell Therapy in Tumors

Exploration of Payment Methods for CAR-T Cell Therapy

Market Opportunities and Challenges for TIL Therapy

Research Progress of CAR-NK Cell Therapy in the Treatment of Hematological Tumors

Development Strategies for CAR-T Cell Therapy Targeting Glioblastoma

Development and Challenges of CAR-T Cell Therapy Derived from Cord Blood

Clinical Exploration of CLDN18.2-Targeted CAR-T in Solid Tumors

Application of mRNA Technology in CAR Cell Therapy

Advances in TCR-T Cell Therapy for Solid Tumors

Development Strategies for CAR-M Cell Therapy

Roundtable: Feasibility Discussion on the Global Commercialization of Cell Drugs Entering a Boom Period

Roundtable: Technological Innovation Opportunities in Tumor Immunocyte Therapy

Scan the code

Limited Time Offer

Free Tickets

Hotline for Cooperation

18701871600 (Manager Wang)

15572286596 (Manager Yuan)

15221150919 (Manager He)

About Juncell Therapeutics

Juncell Therapeutics focuses on the field of solid tumor treatment, committed to developing high-quality and highly accessible TIL cell-based therapeutics. It has been recognized as a National High-tech Enterprise and a Shanghai-based specialized and innovative small and medium-sized enterprise.

The company independently established the internationally leading DeepTIL.^®Cell Enrichment Amplification and NovaGMP^®Gene Modification Technology Platform: A Disruptive Solution to Key Common Issues in TIL Therapy, Achieving Multi-Level Goals for TIL Cells to Be "Cultivable, Well-Cultivated, Affordable, and Easy-to-Use." Two TIL cell drugs currently in clinical stages have demonstrated excellent safety and efficacy in treating nine types of advanced solid tumors (including pancreatic cancer and high-grade gliomas that failed multiple lines of treatment). Among them, six advanced patients achieved complete tumor clearance with CR outcomes, and the longest tumor-free survival time has approached three years.

To seize the opportunities currently facing the industry and promote common development.MedCareer will host the 2024 IBI EXPO Biopharmaceutical Innovation Conference in Nanjing, China on June 14-15, 2024., and convened "Tumor Immunocyte Therapy Seminar". This conference will invite pioneers and leaders in this field, focus on the latest research trends and advancements, and deeply explore and forecast the future development trends of cell therapy drug development.

  //  

2024 IBI EXPO Schedule Overview

Scan the code

Time-limited Claim

Free Tickets

DianDian "Share”、“Like" and "In View"，Give me a little recharge~"